•
Sep 30, 2021
Cencora Q4 2021 Earnings Report
AmerisourceBergen reported strong fourth quarter and fiscal year 2021 results, marked by a revenue increase of 19.6% and adjusted diluted EPS growth of 26.5%.
Key Takeaways
AmerisourceBergen's Q4 2021 revenue increased by 19.6% to $58.9 billion. GAAP diluted EPS was $2.08, while adjusted diluted EPS increased by 26.5% to $2.39. The company's performance was driven by growth in Pharmaceutical Distribution Services and the acquisition of Alliance Healthcare.
Revenue increased 19.6% to $58.9 billion for the fourth quarter.
GAAP diluted EPS was $2.08 for the fourth quarter.
Adjusted diluted EPS increased 26.5% to $2.39 for the fourth quarter.
Revenue increased 12.7% to $214.0 billion for fiscal year 2021.
Cencora
Cencora
Cencora Revenue by Segment
Forward Guidance
AmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable segments.
Positive Outlook
- Revenue growth in the high-single digit to low-double digit percent range
- U.S. Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%
- International Healthcare Solutions revenue of approximately $26 to $27 billion
- Adjusted diluted earnings per share to be in the range of $10.50 to $10.80
- Adjusted operating income growth in the mid- to high-teens percent range
Challenges Ahead
- Interest expense growth to be in the mid-teens percent range
- Adjusted effective tax rate to be approximately 21 percent to 22 percent
- Adjusted free cash flow to be approximately $2 to $2.5 billion
- Capital expenditures in the $500 million range
- Weighted average diluted shares are expected to be approximately 212 million for the fiscal year